产品
编 号：F468903
分子式：C22H25N3O4
分子量：395.45
分子式：C22H25N3O4
分子量：395.45
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 81840-15-5
产品详情
生物活性：
Vesnarinone (OPC-8212) is an orally active phosphodiesterase 3 (PDE3) inhibitor. Vesnarinone can increase in calcium flux and decrease in potassium flux. Vesnarinone shows dose-dependent positive inotropic activity. Vesnarinone can be used in heart failure research.
体内研究：
Vesnarinone (oral gavage; 300 mg/kg; once daily; 6 w) binds covalently to rat liver in vivo.Animal Model:Female Lewis rats (200 g)
Dosage:300 mg/kg
Administration:Oral gavage; 300 mg/kg; once daily; 6 weeks
Result:Observed covalently modified liver proteins.
体外研究：
Vesnarinone (60 and 100 μg/mL; 48 h) inhibits the cell growth in a dose-dependent manner.Vesnarinone (60 μg/mL; 48 h) induces G1 arrest and apoptosis.Vesnarinone (60 μg/mL; 0, 12, 24, and 48 h) treatment increases p21-mRNA expression and decreases p21 protein slightly.
Vesnarinone (OPC-8212) is an orally active phosphodiesterase 3 (PDE3) inhibitor. Vesnarinone can increase in calcium flux and decrease in potassium flux. Vesnarinone shows dose-dependent positive inotropic activity. Vesnarinone can be used in heart failure research.
体内研究：
Vesnarinone (oral gavage; 300 mg/kg; once daily; 6 w) binds covalently to rat liver in vivo.Animal Model:Female Lewis rats (200 g)
Dosage:300 mg/kg
Administration:Oral gavage; 300 mg/kg; once daily; 6 weeks
Result:Observed covalently modified liver proteins.
体外研究：
Vesnarinone (60 and 100 μg/mL; 48 h) inhibits the cell growth in a dose-dependent manner.Vesnarinone (60 μg/mL; 48 h) induces G1 arrest and apoptosis.Vesnarinone (60 μg/mL; 0, 12, 24, and 48 h) treatment increases p21-mRNA expression and decreases p21 protein slightly.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备